CordenPharma Expands into Oligonucleotide APIs
PTSM: Pharmaceutical Technology Sourcing and Management
The company will expand its service offerings to include oligonucleotide API development and manufacture.
On July 1, 2016, CordenPharma announced that the company will expand into the oligonucleotide API development and manufacturing market. Corden has already begun to expand its Boulder, Colorado facility for the manufacture and development of oligonucleotide APIs. The expansion of the Colorado facility is expected to be complete by the end of 2016. This move will broaden the company’s service offerings, which currently include peptides, lipids, and carbohydrates for APIs and drug products.
“Based on the rich pipeline in the growing oligonucleotide field, this is a very logical move for CordenPharma within our current API and drug product manufacturing offerings,” Mimoun Ayoub, director Peptides, Lipids, Carbohydrates and Injectables Platforms, at CordenPharma International, said in a press statement. “The expansion into the oligonucleotide market is a synergistic complement to our outstanding experience in the manufacture of synthetic lipids, peptides, and carbohydrates, which are also used in oligonucleotide drug delivery.”
Source: CordenPharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
